Spots Global Cancer Trial Database for MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey

Official Title: Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey

Study ID: NCT04727294

Conditions

Multiple Myeloma

Smoldering Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance

Coronavirus

Interventions

Questionnaire

Study Description

Brief Summary: The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.

Detailed Description: